Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director | June 01, 2022 | June 03, 2022 |
| ViewRay, Inc.VRAY · Entity 111118 | Director | November 15, 2017 | April 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date June 01, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 305,475 |
Reported balance
After 2022-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-06-01 · Exercise / conversion · Acquired 3,036 · Balance 305,475 F1: This reflects the number of restricted stock units that vested on June 1, 2022. F2: The shares of common stock for Dr. Gold include 31,900 shares held directly, 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 22,000 shares held by Dr. Gold's spouse in revocable trusts, and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-01 · Exercise / conversion · Disposed 3,036 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,459 |
Reported balance
After 2022-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-01 · Grant · Acquired 6,459 · Balance 6,459 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. |
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $9.29 · Expires 2032-06-01 | Direct | 11,811 |
Reported balance
After 2022-06-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-06-01 · Grant · Acquired 11,811 · Balance 11,811 F5: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units that vested on June 1, 2022.
F2: The shares of common stock for Dr. Gold include 31,900 shares held directly, 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 22,000 shares held by Dr. Gold's spouse in revocable trusts, and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust.
F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.
F5: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.
ViewRay, Inc.
Report date November 15, 2017 · Filed April 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 138,767 |
Reported balance
After 2017-11-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-11-15 · Grant · Acquired 5,610 · Balance 138,767 F1: The reported securities are fully vested RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon the earlier of (i) the Reporting Person's termination of service from the Issuer's board of directors or (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan. F2: Includes 20,581 RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 163,871 |
Reported balance
After 2017-12-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-12-01 · Exercise / conversion · Acquired 25,104 · Balance 163,871 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 101,174 |
Reported balance
After 2017-12-03 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2017-12-03 · Other · Acquired 9,389 · Balance 101,174 F3: Securities held by JMSK, Ltd. F5: Janice Gold, the wife of Dr. Gold, is the President of MJSK, Ltd., and Steven Gold, the son of Dr. Gold, is the General Partner of JMSK, Ltd. Voting and dispositive decisions with respect to securities held by MJSK, Ltd. and JMSK, Ltd. are not made by Dr. Gold; he disclaims beneficial ownership of the securities held by MJSK, Ltd. and JMSK, Ltd. except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 54,129 |
Reported balance
Holding disclosure · report date 2017-11-15 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 54,129 F4: Securities held by MJSK, Ltd. F5: Janice Gold, the wife of Dr. Gold, is the President of MJSK, Ltd., and Steven Gold, the son of Dr. Gold, is the General Partner of JMSK, Ltd. Voting and dispositive decisions with respect to securities held by MJSK, Ltd. and JMSK, Ltd. are not made by Dr. Gold; he disclaims beneficial ownership of the securities held by MJSK, Ltd. and JMSK, Ltd. except to the extent of his pecuniary interest therein, if any. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.02 · Expires 2027-11-15 | Direct | 45,633 |
Reported balance
After 2017-11-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-11-15 · Grant · Acquired 45,633 · Balance 45,633 F6: 27,174 of the shares subject to the option were fully vested on November 15, 2017. 1/12 of the remaining 18,459 shares subject to the option vested and became exercisable on each monthly anniversary measured from June 19, 2017, such that 100% of the shares subject to the option will fully vest on June 19, 2018. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2023-08-22 | Direct | 0 |
Reported balance
After 2017-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-12-01 · Exercise / conversion · Acquired 25,104 · Balance 0 |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.17 · Expires 2024-01-18 | IndirectSee footnote | 0 |
Reported balance
After 2017-12-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-12-03 · Other · Acquired 9,389 · Balance 0 F3: Securities held by JMSK, Ltd. F5: Janice Gold, the wife of Dr. Gold, is the President of MJSK, Ltd., and Steven Gold, the son of Dr. Gold, is the General Partner of JMSK, Ltd. Voting and dispositive decisions with respect to securities held by MJSK, Ltd. and JMSK, Ltd. are not made by Dr. Gold; he disclaims beneficial ownership of the securities held by MJSK, Ltd. and JMSK, Ltd. except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are fully vested RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon the earlier of (i) the Reporting Person's termination of service from the Issuer's board of directors or (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan.
F2: Includes 20,581 RSUs.
F3: Securities held by JMSK, Ltd.
F4: Securities held by MJSK, Ltd.
F5: Janice Gold, the wife of Dr. Gold, is the President of MJSK, Ltd., and Steven Gold, the son of Dr. Gold, is the General Partner of JMSK, Ltd. Voting and dispositive decisions with respect to securities held by MJSK, Ltd. and JMSK, Ltd. are not made by Dr. Gold; he disclaims beneficial ownership of the securities held by MJSK, Ltd. and JMSK, Ltd. except to the extent of his pecuniary interest therein, if any.
F6: 27,174 of the shares subject to the option were fully vested on November 15, 2017. 1/12 of the remaining 18,459 shares subject to the option vested and became exercisable on each monthly anniversary measured from June 19, 2017, such that 100% of the shares subject to the option will fully vest on June 19, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2022 Filed Jun 3, 2022 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 11,811 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0000805928-22-000063 · wf-form4_165428683027747.xml · derivative · entry 4 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,811 Underlying: Common Stock · 11,811 shares Expires 2032-06-01 F5 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000063 · wf-form4_165428683027747.xml · derivative · entry 3 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 Underlying: Common Stock · 6,459 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F5 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000063 · wf-form4_165428683027747.xml · derivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,036 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000063 · wf-form4_165428683027747.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022. F2 · balance_after: The shares of common stock for Dr. Gold include 31,900 shares held directly, 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 22,000 shares held by Dr. Gold's spouse in revocable trusts, and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000113 · wf-form4_162275490582369.xml · derivative · entry 4 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,036 Underlying: Common Stock · 3,036 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to buy) · Derivative | 6,030 | $0.00 Strike: $19.76 | $0.00 |
DisclosureSEC source: 0000805928-21-000113 · wf-form4_162275490582369.xml · derivative · entry 3 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires 2031-06-01 F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000113 · wf-form4_162275490582369.xml · derivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: This reflects the number of restricted stock units that became vested as of June 1, 2021. F3 · derivative.expiration_date: This reflects the number of restricted stock units that became vested as of June 1, 2021. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000113 · wf-form4_162275490582369.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The shares of common stock for Dr. Gold include 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 22,000 shares held by Dr. Gold's spouse in revocable trusts, and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:19 UTC | Axogen, Inc. AXGN · Entity 4297 | GiftCommon Stock | 15,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-010849 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 296,266 F1 · shares: The shares of common stock for Dr. Gold include 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his adult children who do not share a household with Dr. Gold. F1 · balance_after: The shares of common stock for Dr. Gold include 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his adult children who do not share a household with Dr. Gold. F1 · ownership.direct: The shares of common stock for Dr. Gold include 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his adult children who do not share a household with Dr. Gold. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 15:05 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,591 | $11.75 | $30,444.25 |
DisclosureSEC source: 0001179110-20-009614 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,862 F1 · shares: The shares of common stock for Dr. Gold include 175,171 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the number of restricted stock units that became vested as of September 3, 2020. Read SEC document |
| August 12, 2020 Filed Aug 13, 2020 19:25 UTC | Axogen, Inc. AXGN · Entity 4297 | GiftCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-008985 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 309,271 F1 · balance_after: The shares of common stock for Dr. Gold include 175,171 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his grandchildren pursuant to the Uniform Transfer to Minors Act who do not share a household with Dr. Gold. F1 · ownership.direct: The shares of common stock for Dr. Gold include 175,171 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his grandchildren pursuant to the Uniform Transfer to Minors Act who do not share a household with Dr. Gold. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:20 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007279 · edgar.xml · derivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,173 Underlying: Common Stock · 6,173 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · date: The original Form 4 filed on June 3, 2020, is a duplicate filing. The correct information is being submitted in this Form 4/A. F3 · shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The correct information is being submitted in this Form 4/A. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The correct information is being submitted in this Form 4/A. F3 · balance_after: The original Form 4 filed on June 3, 2020, is a duplicate filing. The correct information is being submitted in this Form 4/A. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:20 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 12,605 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-007279 · edgar.xml · derivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,605 Underlying: Common Stock · 12,605 shares Expires 2030-06-01 F3 · derivative.exercise_price: The original Form 4 filed on June 3, 2020, is a duplicate filing. The correct information is being submitted in this Form 4/A. F3 · date: The original Form 4 filed on June 3, 2020, is a duplicate filing. The correct information is being submitted in this Form 4/A. F3 · shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The correct information is being submitted in this Form 4/A. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.expiration_date: The original Form 4 filed on June 3, 2020, is a duplicate filing. The correct information is being submitted in this Form 4/A. F3 · derivative.underlying_shares: The original Form 4 filed on June 3, 2020, is a duplicate filing. The correct information is being submitted in this Form 4/A. F3 · balance_after: The original Form 4 filed on June 3, 2020, is a duplicate filing. The correct information is being submitted in this Form 4/A. Read SEC document |
| December 03, 2019 Filed Dec 6, 2019 01:40 UTC | Axogen, Inc. AXGN · Entity 4297 | GiftCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-012473 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 326,771 F1 · balance_after: The shares of common stock for Dr. Gold include 192,671 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his adult children who do not share a household with Dr. Gold. F1 · ownership.direct: The shares of common stock for Dr. Gold include 192,671 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his adult children who do not share a household with Dr. Gold. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 23:03 UTC | Axogen, Inc. AXGN · Entity 4297 | GiftCommon Stock | 13,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-012093 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 333,771 F1 · balance_after: The shares of common stock for Dr. Gold include 199,671 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his grandchildren pursuant to the Uniform Transfer to Minors Act who do not share a household with Dr. Gold. F1 · ownership.direct: The shares of common stock for Dr. Gold include 199,671 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his grandchildren pursuant to the Uniform Transfer to Minors Act who do not share a household with Dr. Gold. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:31 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010088 · edgar.xml · derivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 2,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:31 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 10,710 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001179110-19-010088 · edgar.xml · derivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Underlying: Common Stock · 10,710 shares Expires 2029-09-03 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Jun 3, 2020 20:34 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006889 · edgar.xml · derivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 2,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Jun 3, 2020 20:34 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 10,710 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001179110-20-006889 · edgar.xml · derivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Underlying: Common Stock · 10,710 shares Expires 2029-09-03 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| August 09, 2019 Filed Aug 15, 2019 20:03 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 100 | $13.04 | $1,304.00 |
DisclosureSEC source: 0001179110-19-009535 · edgar.xml · nonDerivative · entry 6 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 348,761 F2 · balance_after: The shares of common stock for Dr. Gold indirect ownership of 2,000 shares held by The Janice Gold Living Trust dated 10-30-17, IA. F2 · ownership.direct: The shares of common stock for Dr. Gold indirect ownership of 2,000 shares held by The Janice Gold Living Trust dated 10-30-17, IA. Read SEC document |
| August 09, 2019 Filed Aug 15, 2019 20:03 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 700 | $13.05 | $9,135.00 |
DisclosureSEC source: 0001179110-19-009535 · edgar.xml · nonDerivative · entry 5 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 348,661 F2 · balance_after: The shares of common stock for Dr. Gold indirect ownership of 2,000 shares held by The Janice Gold Living Trust dated 10-30-17, IA. F2 · ownership.direct: The shares of common stock for Dr. Gold indirect ownership of 2,000 shares held by The Janice Gold Living Trust dated 10-30-17, IA. Read SEC document |
| August 09, 2019 Filed Aug 15, 2019 20:03 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 1,000 | $13.13 | $13,130.00 |
DisclosureSEC source: 0001179110-19-009535 · edgar.xml · nonDerivative · entry 4 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 347,961 F2 · balance_after: The shares of common stock for Dr. Gold indirect ownership of 2,000 shares held by The Janice Gold Living Trust dated 10-30-17, IA. F2 · ownership.direct: The shares of common stock for Dr. Gold indirect ownership of 2,000 shares held by The Janice Gold Living Trust dated 10-30-17, IA. Read SEC document |
| August 09, 2019 Filed Aug 15, 2019 20:03 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 100 | $13.04 | $1,304.00 |
DisclosureSEC source: 0001179110-19-009535 · edgar.xml · nonDerivative · entry 3 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 346,961 F2 · balance_after: The shares of common stock for Dr. Gold indirect ownership of 2,000 shares held by The Janice Gold Living Trust dated 10-30-17, IA. F2 · ownership.direct: The shares of common stock for Dr. Gold indirect ownership of 2,000 shares held by The Janice Gold Living Trust dated 10-30-17, IA. Read SEC document |
| August 09, 2019 Filed Aug 15, 2019 20:03 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 100 | $13.04 | $1,304.00 |
DisclosureSEC source: 0001179110-19-009535 · edgar.xml · nonDerivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 346,861 F2 · balance_after: The shares of common stock for Dr. Gold indirect ownership of 2,000 shares held by The Janice Gold Living Trust dated 10-30-17, IA. F2 · ownership.direct: The shares of common stock for Dr. Gold indirect ownership of 2,000 shares held by The Janice Gold Living Trust dated 10-30-17, IA. Read SEC document |
| August 09, 2019 Filed Aug 15, 2019 20:03 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 2,000 | $13.11 | $26,212.00 |
DisclosureSEC source: 0001179110-19-009535 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 346,761 F1 · balance_after: The shares of common stock for Dr. Gold include 49,290 shares held jointly by Dr. Gold and his wife and indirect ownership of 297,471 shares held MJSK, Ltd., a decedent investment trust held by Dr. Gold's Family. F1 · ownership.direct: The shares of common stock for Dr. Gold include 49,290 shares held jointly by Dr. Gold and his wife and indirect ownership of 297,471 shares held MJSK, Ltd., a decedent investment trust held by Dr. Gold's Family. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 00:39 UTC | Axogen, Inc. AXGN · Entity 4297 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-012049 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,761 F1 · balance_after: The shares of common stock for Dr. Gold include 212,761 shares held jointly by Dr. Gold and his wife and indirect ownership of 122,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the transfer of 20,000 indirect ownership shares held by Dr. Gold's spouse to MJKS, Ltd. F1 · ownership.direct: The shares of common stock for Dr. Gold include 212,761 shares held jointly by Dr. Gold and his wife and indirect ownership of 122,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the transfer of 20,000 indirect ownership shares held by Dr. Gold's spouse to MJKS, Ltd. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 21:01 UTC | Axogen, Inc. AXGN · Entity 4297 | GiftCommon Stock | 30,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-010554 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,761 F1 · balance_after: The shares of common stock for Dr. Gold include 212,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the transfer by MJKS, Ltd. of an aggregate of 30,487 shares of common stock to Dr. Gold's adult children who do not share a household with Dr. Gold. F1 · ownership.direct: The shares of common stock for Dr. Gold include 212,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the transfer by MJKS, Ltd. of an aggregate of 30,487 shares of common stock to Dr. Gold's adult children who do not share a household with Dr. Gold. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:02 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 4,780 | $0.00 Strike: $49.65 | $0.00 |
DisclosureSEC source: 0001179110-18-008099 · edgar.xml · derivative · entry 3 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,780 Underlying: Common Stock · 4,780 shares Expires 2028-06-01 F2 · derivative.exercise_date: Non-qualified stock option grant for service as Director on the Company's Board of directors. Options vest in equal installments every three months for the first nine months, with the finalinstallment vesting on the earlier of the date of the 2019 annual shareholders meeting or May 31, 2019. Number of shares pursuant to option are based on $120,000 valuation as of the grantdate. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:02 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 15,000 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001179110-18-008099 · edgar.xml · derivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:02 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 15,000 | $14.85 | $222,750.00 |
DisclosureSEC source: 0001179110-18-008099 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The shares of common stock for Dr. Gold include 212,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 122,487 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. F1 · ownership.direct: The shares of common stock for Dr. Gold include 212,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 122,487 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. Read SEC document |
| December 03, 2017 Filed Apr 25, 2018 17:02 UTC | ViewRay, Inc. VRAY · Entity 111118 | OtherWarrant to Purchase Common Stock · Derivative | 9,389 | $3.17 Strike: $3.17 | $29,763.13 |
DisclosureSEC source: 0000950103-18-005158 · dp89957_4-gold.xml · derivative · entry 7 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 9,389 shares Expires 2024-01-18 F3 · ownership.nature: Securities held by JMSK, Ltd. F5 · ownership.nature: Janice Gold, the wife of Dr. Gold, is the President of MJSK, Ltd., and Steven Gold, the son of Dr. Gold, is the General Partner of JMSK, Ltd. Voting and dispositive decisions with respect to securities held by MJSK, Ltd. and JMSK, Ltd. are not made by Dr. Gold; he disclaims beneficial ownership of the securities held by MJSK, Ltd. and JMSK, Ltd. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 03, 2017 Filed Apr 25, 2018 17:02 UTC | ViewRay, Inc. VRAY · Entity 111118 | OtherCommon Stock | 9,389 | $3.17 | $29,763.13 |
DisclosureSEC source: 0000950103-18-005158 · dp89957_4-gold.xml · nonDerivative · entry 3 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 101,174 F3 · ownership.nature: Securities held by JMSK, Ltd. F5 · ownership.nature: Janice Gold, the wife of Dr. Gold, is the President of MJSK, Ltd., and Steven Gold, the son of Dr. Gold, is the General Partner of JMSK, Ltd. Voting and dispositive decisions with respect to securities held by MJSK, Ltd. and JMSK, Ltd. are not made by Dr. Gold; he disclaims beneficial ownership of the securities held by MJSK, Ltd. and JMSK, Ltd. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 01, 2017 Filed Apr 25, 2018 17:02 UTC | ViewRay, Inc. VRAY · Entity 111118 | Exercise / conversionWarrant to Purchase Common Stock · Derivative | 25,104 | $2.95 Strike: $2.95 | $74,056.80 |
DisclosureSEC source: 0000950103-18-005158 · dp89957_4-gold.xml · derivative · entry 6 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,104 shares Expires 2023-08-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2017 Filed Apr 25, 2018 17:02 UTC | ViewRay, Inc. VRAY · Entity 111118 | Exercise / conversionCommon Stock | 25,104 | $2.95 | $74,056.80 |
DisclosureSEC source: 0000950103-18-005158 · dp89957_4-gold.xml · nonDerivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2017 Filed Apr 25, 2018 17:02 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantStock Option (right to buy) · Derivative | 45,633 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0000950103-18-005158 · dp89957_4-gold.xml · derivative · entry 5 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,633 Underlying: Common Stock · 45,633 shares Expires 2027-11-15 F6 · derivative.exercise_date: 27,174 of the shares subject to the option were fully vested on November 15, 2017. 1/12 of the remaining 18,459 shares subject to the option vested and became exercisable on each monthly anniversary measured from June 19, 2017, such that 100% of the shares subject to the option will fully vest on June 19, 2018. Read SEC document |
| November 15, 2017 Filed Apr 25, 2018 17:02 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 5,610 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-18-005158 · dp89957_4-gold.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,767 F1 · shares: The reported securities are fully vested RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon the earlier of (i) the Reporting Person's termination of service from the Issuer's board of directors or (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan. F2 · balance_after: Includes 20,581 RSUs. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 16:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 15,000 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001179110-17-014147 · edgar.xml · derivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 16:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 15,000 | $5.09 | $76,350.00 |
DisclosureSEC source: 0001179110-17-014147 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The shares of common stock for Dr. Gold include 197,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 122,487 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. F1 · ownership.direct: The shares of common stock for Dr. Gold include 197,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 122,487 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:48 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 15,000 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001179110-17-008549 · edgar.xml · derivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: Non-qualified stock option grant for service as Director on Company's Board of directors. Options vest in equal installments every three months for the first nine months, with the final installment vesting on the date of the then current annual meeting. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 17:51 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 5,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001179110-17-008297 · edgar.xml · derivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 17:51 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 5,000 | $8.95 | $44,750.00 |
DisclosureSEC source: 0001179110-17-008297 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The shares of common stock for Dr. Gold include 202,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 122,487 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. F1 · ownership.direct: The shares of common stock for Dr. Gold include 202,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 122,487 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. Read SEC document |
| May 22, 2017 Filed May 26, 2017 20:24 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 15,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001179110-17-008083 · edgar.xml · derivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2017 Filed May 26, 2017 20:24 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 15,000 | $4.81 | $72,150.00 |
DisclosureSEC source: 0001179110-17-008083 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The shares of common stock for Dr. Gold include 197,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 122,487 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. F1 · ownership.direct: The shares of common stock for Dr. Gold include 197,761 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 122,487 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 16:34 UTC | ViewRay, Inc. VRAY · Entity 111118 | PurchaseWarrant to Purchase Common Stock · Derivative | 9,389 | $0.13 Strike: $3.17 | $1,173.63 |
DisclosureSEC source: 0001140361-17-002418 · doc1.xml · derivative · entry 5 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 9,389 Underlying: Common Stock · 9,389 shares Expires 2024-01-18 F3 · ownership.nature: Janice Gold, the wife of Dr. Gold, is the President of MJSK, Ltd., and Steven Gold, the son of Dr. Gold, is the General Partner of JMSK, Ltd. Voting and dispositive decisions with respect to securities held by MJSK, Ltd. and JMSK, Ltd. are not made by Dr. Gold; he disclaims beneficial ownership of the securities held by MJSK, Ltd. and JMSK, Ltd. except to the extent of any pecuniary interest therein, if any. F2 · ownership.nature: Securities held by JMSK, Ltd. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 16:34 UTC | ViewRay, Inc. VRAY · Entity 111118 | PurchaseWarrant to Purchase Common Stock · Derivative | 6,259 | $0.13 Strike: $3.17 | $782.38 |
DisclosureSEC source: 0001140361-17-002418 · doc1.xml · derivative · entry 4 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,259 Underlying: Common Stock · 6,259 shares Expires 2024-01-18 Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 16:34 UTC | ViewRay, Inc. VRAY · Entity 111118 | PurchaseCommon Stock | 46,948 | $3.17 | $148,825.16 |
DisclosureSEC source: 0001140361-17-002418 · doc1.xml · nonDerivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 91,785 F3 · ownership.nature: Janice Gold, the wife of Dr. Gold, is the President of MJSK, Ltd., and Steven Gold, the son of Dr. Gold, is the General Partner of JMSK, Ltd. Voting and dispositive decisions with respect to securities held by MJSK, Ltd. and JMSK, Ltd. are not made by Dr. Gold; he disclaims beneficial ownership of the securities held by MJSK, Ltd. and JMSK, Ltd. except to the extent of any pecuniary interest therein, if any. F2 · ownership.nature: Securities held by JMSK, Ltd. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 16:34 UTC | ViewRay, Inc. VRAY · Entity 111118 | PurchaseCommon Stock | 31,298 | $3.17 | $99,214.66 |
DisclosureSEC source: 0001140361-17-002418 · doc1.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,157 F1 · balance_after: Includes 14,971 Restricted Stock Units. Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 21:46 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 5,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001179110-17-000086 · edgar.xml · derivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-12-29 F1 · derivative.exercise_date: Non-qualified stock option grant for service as Director on Company's Board of directors. Vesting is 100% upon the director's re-election to the Company's Board of Directors at the 2017 Annual Meeting of Shareholders. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 20:31 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 14,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-079955 · doc1.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,859 F1 · shares: Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon vesting. 100% of the RSUs shall be fully vested as of the date of grant, however, delivery of the shares will be deferred until the earlier of (i) the Reporting Person's termination of service from the Issuer's board of directors or (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.